12 million people are affected by Hepatitis C in India. India is one of the few countries in the world which have generics for interferon – free treatment, to help combat the disease. Also, fresh hope to patients as the Apex Committee of the Central Drugs Standard Control Organisation (CDSCO), has granted a waiver of local trials for crucial new direct-acting antiviral drugs sofosbuvir and ledipasvir for treatment of Hepatitis C. This is expected to bring down the costs of the generic drugs within weeks. The union health ministry of India is also planning to make a mandatory system of prescribing drugs with their generic names.

Where the treatment costs over US $90,000 in the US and US $60,000 in the EU, it is expected to cost US $1000 or less in India due to the availability of generics. To know more about the treatments available in India and their costs – refer to The Holiday Healer Treatment Cost Comparison Page.

It is expected to revolutionize the treatment of Hep C similar to that the Indian generics contributed to AIDS/HIV treatment. Currently medical tourism in this sector is strong and has managed to help patients from all across the world.

Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month (More Statistics about Registration in India). The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.